Martin B. Silverstein

Martin (Marty) Silverstein, M.D., is currently the President and Chief Executive Officer of MANA Therapeutics, an adoptive T-cell therapy company developing allogeneic, non-engineered, multi-tumor associated antigens targeting a range of liquid and solid tumors. He joined MANA after its original seed round, and led the successful financing of their Series A round in 2021. Prior to MANA, Dr. Silverstein was Executive Vice President, Strategy for Gilead Sciences, a leading biotechnology company, where his responsibilities included corporate strategy and planning, commercial planning, corporate development, and alliance management. He was an integral part of Gilead’s acquisition of Kite Pharma. Immediately prior to Gilead, Dr. Silverstein was Executive Vice President and Chief Strategy Officer at Anthem, the second-largest U.S. health insurer. His responsibilities at Anthem included corporate strategy and innovation, corporate development, and enterprise marketing. Prior to Anthem, Dr. Silverstein was a Senior Partner and Managing Director at The Boston Consulting Group (BCG), where he was a founding member of its health care practice and recognized for his role in establishing its pharmaceutical practice. While at BCG, he held roles of increasing responsibility including Global Leader of the health care practice. Dr. Silverstein received his medical degree from Yale University, and his MBA from the Harvard Business School. He graduated summa cum laude from the University of Pennsylvania with a degree in economics. Dr. Silverstein completed his internal medicine residency at Boston’s Beth Israel Hospital, a major teaching hospital of Harvard Medical School, and is board certified in internal medicine.